Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 52,000 Shares

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 52,000 shares of the stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total transaction of $702,520.00. Following the sale, the chief financial officer owned 68,148 shares in the company, valued at $920,679.48. This represents a 43.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Dominic Piscitelli also recently made the following trade(s):

• On Tuesday, December 16th, Dominic Piscitelli sold 10,720 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $9.06, for a total transaction of $97,123.20.

Oric Pharmaceuticals Price Performance

NASDAQ ORIC opened at $13.50 on Friday. The business has a fifty day moving average price of $10.28 and a two-hundred day moving average price of $10.97. The stock has a market capitalization of $1.35 billion, a PE ratio of -8.88 and a beta of 1.35. Oric Pharmaceuticals, Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. As a group, sell-side analysts expect that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Key Oric Pharmaceuticals News

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised Q1–Q4 and FY2026 EPS estimates, cut its FY loss forecast to ($1.28) from ($1.52), reiterated a “Buy” rating and set a $25 price target (up from $23). This analyst upgrade and higher target support upside expectations. H.C. Wainwright raises estimates and price target
• Positive Sentiment: Consensus/price-target commentary highlights substantial analyst upside — Zacks notes the mean analyst target implies ~58.4% upside, which can attract momentum buyers. Zacks: analyst mean implies large upside
• Positive Sentiment: Wedbush assigned an “Outperform” rating, adding to bullish analyst sentiment that likely helped lift the shares. Wedbush Outperform
• Positive Sentiment: ORIC reported an earnings beat (Q4 EPS of ($0.30) vs. consensus ($0.34)), a near-term catalyst that pushed the stock higher. The earnings surprise appears to be the immediate driver of today’s rally. Earnings beat and stock reaction
• Neutral Sentiment: Despite upgrades, consensus estimates still show ORIC operating at a multi-quarter loss (current full-year consensus around ($2.17) per share), so upside hinges on continued clinical progress and margin improvements. MarketBeat consensus background
• Negative Sentiment: CFO Dominic Piscitelli sold 52,000 shares at ~$13.51 (about $702.5k), reducing his stake by ~43%; insider selling can be perceived negatively by investors and may moderate price gains. SEC filing: SEC Form 4 — CFO sale

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ORIC. Vanguard Group Inc. increased its stake in shares of Oric Pharmaceuticals by 48.8% in the third quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock valued at $55,802,000 after buying an additional 1,525,445 shares during the period. Alkeon Capital Management LLC boosted its holdings in Oric Pharmaceuticals by 12.5% in the second quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock valued at $45,717,000 after acquiring an additional 500,000 shares during the last quarter. State Street Corp increased its position in Oric Pharmaceuticals by 77.1% during the 4th quarter. State Street Corp now owns 4,258,397 shares of the company’s stock valued at $34,834,000 after purchasing an additional 1,854,458 shares during the period. Orbimed Advisors LLC raised its holdings in Oric Pharmaceuticals by 305.0% during the 3rd quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock worth $43,701,000 after purchasing an additional 2,742,475 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Oric Pharmaceuticals by 14.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,295,122 shares of the company’s stock worth $26,955,000 after purchasing an additional 423,795 shares during the period. 95.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ORIC shares. JPMorgan Chase & Co. lifted their price target on shares of Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Piper Sandler initiated coverage on shares of Oric Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “overweight” rating and a $22.00 target price on the stock. Wall Street Zen downgraded shares of Oric Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 23rd. Wedbush reiterated an “outperform” rating and issued a $20.00 price target on shares of Oric Pharmaceuticals in a research note on Tuesday. Finally, HC Wainwright boosted their price objective on Oric Pharmaceuticals from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Oric Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $20.20.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.